Next Article in Journal
Exertional Heat Stroke, Modality Cooling Rate, and Survival Outcomes: A Systematic Review
Next Article in Special Issue
Nandrolone Decanoate: Use, Abuse and Side Effects
Previous Article in Journal
Hemithyroidectomy for Thyroid Cancer: A Review
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Sudden Cardiac Death in Anabolic-Androgenic Steroid Users: A Literature Review

1
Legal Medicine, Department of Medical, Surgical and Advanced Technologies, “G.F. Ingrassia”, University of Catania, 95123 Catania, Italy
2
Department of Law, Criminology, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy
3
Department of History, Society and Studies on Humanity, University of Salento, 73100 Lecce, Italy
*
Author to whom correspondence should be addressed.
Medicina 2020, 56(11), 587; https://doi.org/10.3390/medicina56110587
Submission received: 30 September 2020 / Revised: 29 October 2020 / Accepted: 2 November 2020 / Published: 4 November 2020

Abstract

:
Background and objectives: Anabolic-androgenic steroids (AASs) are a group of synthetic molecules derived from testosterone and its related precursors. AASs are widely used illicitly by adolescents and athletes, especially by bodybuilders, both for aesthetic uses and as performance enhancers to increase muscle growth and lean body mass. When used illicitly they can damage health and cause disorders affecting several functions. Sudden cardiac death (SCD) is the most common medical cause of death in athletes. SCD in athletes has also been associated with the use of performance-enhancing drugs. This review aimed to focus on deaths related to AAS abuse to investigate the cardiac pathophysiological mechanism that underlies this type of death, which still needs to be fully investigated. Materials and Methods: This review was conducted using PubMed Central and Google Scholar databases, until 21 July 2020, using the following key terms: “((Sudden cardiac death) OR (Sudden death)) AND ((androgenic anabolic steroid) OR (androgenic anabolic steroids) OR (anabolic-androgenic steroids) OR (anabolic-androgenic steroid))”. Thirteen articles met the inclusion and exclusion criteria, for a total of 33 reported cases. Results: Of the 33 cases, 31 (93.9%) were males while only 2 (61%) were females. Mean age was 29.79 and, among sportsmen, the most represented sports activity was bodybuilding. In all cases there was a history of AAS abuse or a physical phenotype suggesting AAS use; the total usage period was unspecified in most cases. In 24 cases the results of the toxicological analysis were reported. The most detected AASs were nandrolone, testosterone, and stanozolol. The most frequently reported macroscopic alterations were cardiomegaly and left ventricular hypertrophy, while the histological alterations were foci of fibrosis and necrosis of the myocardial tissue. Conclusions: Four principal mechanisms responsible for SCD have been proposed in AAS abusers: the atherogenic model, the thrombosis model, the model of vasospasm induced by the release of nitric oxide, and the direct myocardial injury model. Hypertrophy, fibrosis, and necrosis represent a substrate for arrhythmias, especially when combined with exercise. Indeed, AAS use has been shown to change physiological cardiac remodeling of athletes to pathophysiological cardiac hypertrophy with an increased risk of life-threatening arrhythmias.

1. Introduction

AASs are a group of synthetic molecules derived from testosterone and its related precursors. AAS were developed to minimize the androgenic effects of testosterone and maximize the anabolic effects promoting the growth of skeletal muscles [1,2,3]. AASs can be administered orally, by intramuscular or subcutaneous injection, by pellet subcutaneous implantation, or by application on the skin.
Only a few AAS are used or proposed for therapeutic use, mainly in replacement treatment of hypogonadism [4,5]. Direct testosterone replacement therapy (TRT) is the only FDA-approved therapy for the treatment of male hypogonadism [6]. Oxandrolone, instead, is used to fight the protein catabolism associated with long-term use of corticosteroids and in the treatment of bone pain due to osteoporosis [7]. Clinical studies have demonstrated the efficacy of oxandrolone in the treatment of acute catabolic disorders, such as severe burns or severe trauma, and chronic catabolic disorders such as AIDS-associated cachexia or neuromuscular diseases such as Duchenne muscular dystrophy [8]. As well as for therapeutic use, AAS are widely used illicitly by adolescents and athletes, especially by bodybuilders, both for aesthetic uses and as performance enhancers to increase muscle growth and lean body mass, in consideration of their significant anabolic effect [9,10].
Although the use of AASs is now widespread around the world, with around ten million users, there are some geographical differences. The Middle East has the highest prevalence rate, with 21.7% of world users, followed by South America (4.8%), Europe (3.8%), North America (3.0%), Oceania (2.6%), Africa (2.4%), and Asia (0.2%). Among developed countries, the highest prevalence is found in Scandinavia, the United States, and countries of the British Commonwealth. The highest overall prevalence rate of AAS use was found in recreational sportspeople (18.4%), followed by athletes (13.4%), prisoners (12.4%), and drug users (8.0%). Non-athletes have the lowest prevalence rate that is estimated to be about 1% [11,12]. The global lifetime prevalence rate of AAS use is estimated to be 3.3%, greater in men than women (6.4% vs. 1.6%). As concerns the age of AAS users, teenagers have a higher overall prevalence rate (2.5%) than people older than 19 years (1.9%). The prevalence rate among high-school students was 2.3% [11,13,14].
While the use of AASs for medical indications is relatively safe, when used illicitly they can damage health and cause disorders affecting several functions (cardiovascular, reproductive, musculoskeletal, endocrine, renal, immunologic, and neuropsychiatric) [3,15,16,17,18,19,20,21,22,23]. These side effects include cardiac injuries such as fibrosis, cardiac hypertrophy, and dilated cardiomyopathy with an increased risk for myocardial infarction, arrhythmias, and sudden cardiac death [3,24,25,26,27].
AAS are typically used in phases referred to as “cycles”. To reduce the dangerous consequences of continuous AAS use at supraphysiological doses, abusers often introduce changes to their intake [28,29]. “Stacking” consumption can also involve nutritional supplements, complements, or other substances [30,31,32]. The substances most frequently taken at the same time as AASs are alcohol, amphetamines, aspirin, cannabinoids, caffeine, clomiphene citrate, cocaine, codeine, creatine, ephedrine, erythropoietin, furosemide, gamma-hydroxybutyrate (GHB), growth hormone, heroin, insulin, insulin-like growth 1 (IGF-1), melanotan, protein powder, tamoxifen, thyroxine, and tobacco. [33].
Sudden cardiac death (SCD) is generally defined as a sudden unexpected death or arrest from a presumed cardiac cause, which occurs within one hour of symptom onset if witnessed, otherwise within 24 h, in a person without any prior condition that would appear fatal [34,35,36].
This review aims to investigate the relationship between the use of anabolic-androgenic steroids (AAS) and sudden cardiac death in athletes and identify the possible etiological mechanism.

2. Materials and Methods

2.1. Database Search Terms and Timeline

This review was conducted performing a systematic literature search on online resources (PubMed Central database and Google Scholar) until 21 July 2020, using the following key terms: “((Sudden cardiac death) OR (Sudden death)) AND ((androgenic anabolic steroid) OR (androgenic anabolic steroids) OR (anabolic-androgenic steroids) OR (anabolic-androgenic steroid))”.

2.2. Inclusion and Exclusion Criteria

The following inclusion criterion were applied: full-text scientific article published in English. The following exclusion criteria were adopted: (1) conference abstracts or reviews and letters to the editor without case reports; (2) animal studies; (3) articles in which the correlation between cardiac death and steroids is not discussed; (4) articles regarding surviving subjects.

2.3. Study Selection

We retrieved 1909 articles (339 from Pubmed Central and 1570 from Google Scholar databases). After excluding all duplicate articles, the reviewers retrieved abstracts and full text of each article independently applying the inclusion and exclusion criteria. Figure 1 summarizes the data obtained after our literature search.

3. Results

The review of the literature using the flow diagram shown in Figure 1 allowed us to identify 13 articles (Table 1) published between 1993 and 2020, for a total of 33 reported cases. The main characteristics of each selected article are summarized in Appendix A.
Of the 33 cases, 31 (93.9%) were males while only 2 (6.1%) were females. The mean age was 29.79 years with an SD of 8.5 years (range 13–54). Twenty-one cases (63.6%) were sportsmen and the most represented sports activity was bodybuilding (13 cases, 39%).
In all cases, there was a history of AAS abuse or a physical phenotype suggesting AAS use, the total period of AAS use was unspecified in 24 cases. In the other 9 cases, the time in which the subjects took AAS varied from 3 months to several years. In 24 cases the results of the toxicological analysis were reported. The tests were negative in 4 subjects. In 8 individuals, the toxicological examination revealed the presence of one or more AASs (Table 2) in blood or urine. The most detected AASs were nandrolone (10 cases), testosterone (9 cases), and stanozolol (7 cases). In two cases the toxicological examination found the presence of other substances used as performance-enhancing drugs (clenbuterol, ephedrine, norephedrine, liothyronine). In five other cases, other drugs of abuse were found such as cocaine, opioids, benzodiazepines, and cannabinoids.
In 15 cases it was possible to calculate the weight of the heart as a percentage of body weight (Appendix A). Anamnestic data were present in 24 of the 33 cases examined (72.7%). Of these, in no case was there a personal history of the disease or a family history of heart disease before age 50.
In the 33 examined cases, the most frequent macroscopic alteration was cardiomegaly (11 cases, 33%), based on the weight of the heart as a percentage of body weight, followed by left ventricular hypertrophy (10 cases, 30%). Dilated cardiomyopathy was found in 3 cases (9%). The most frequently reported histological alteration were foci of fibrosis and necrosis of the myocardial tissue, found respectively in 21 (79%) and 17 cases (52%). Other histological alterations reported were atherosclerosis (7 cases, 21%), inflammatory infiltrate (4 cases, 12%), coronary stenosis (3 cases, 9%), and left ventricular apoplexy (2 cases, 6%). The macroscopic and histological findings are summarized in Figure 2.

4. Discussion

Data emerging from our study confirm the higher prevalence of ASS assumption among young males (93.9% males compared to 6.1%females, mean age 29.79 years), especially if they are bodybuilders (39%). In none of the cases in which anamnestic data were present was there a personal history of the disease or a family history of heart disease before age 50. In the 33 cases examined, the most frequently reported macroscopic changes were cardiomegaly (33%) and left ventricular hypertrophy (30%). The most frequently reported histological changes were foci of fibrosis (79%) and necrosis (52%) of myocardial tissue. In all cases, autopsies ruled out causes of extracardiac death, and SCD was correlated with AAS use. Sudden cardiac death (SCD) is generally defined as a sudden unexpected death or arrest from a presumed cardiac cause, which occurs within one hour of symptom onset if witnessed, otherwise within 24 h, in a person without any prior condition that would appear fatal [34,35,36]. SCD in athletes is an event that profoundly impacts society because athletes are generally seen as a healthy category of people. Although SCD is the most common medical cause of death in athletes, its true incidence is unknown. The risk of SCD in athletes is 2 to 3 times greater than that in the general population. This difference may be due to typical athletes' demographic factors, such as sex, age, and ethnicity. Potential mechanisms for SCD consist of inflammation, mechanical factors such as ventricular hypertrophy or fibrosis, neurological and metabolic comorbidities, and hereditary factors, arrhythmic mechanisms of abnormal ventricular repolarization, conduction, or autonomic innervation [49]. The etiology of SCD in younger athletes (<35 years of age) is mainly related to inherited cardiac conditions, instead, in older athletes, it is related to atherosclerotic coronary artery disease (CAD) [50,51,52,53]. Left ventricular hypertrophy (LVH) has been recognized as an independent risk factor for sudden cardiac death. The high mortality and sudden cardiac death associated with LVH is related to ventricular arrhythmia. Indeed, hypertrophied myocardium has a typical pro-arrhythmic electrophysiological phenotype and predisposes to the presence of myocardial ischemia. The main abnormality is prolongation of the action potential duration and refractoriness, which represents the substrate for arrhythmias [54]. Increased risk of ventricular arrhythmias and SCD, associated with hypertrophy, are related to complex processes involving myocardial cells, interstitium, coronary flow reserve, and neurohumoral activation [55]. SCD in athletes has also been associated with the use of performance-enhancing drugs, both anabolic-androgenic steroids and nonsteroidal agents [56]. AAS users often combine the assumption of anabolic substances with other substances such as cocaine, methamphetamine, and smart drugs. These data are in agreement with the results of our review. Mixing two or more substances increases the risk of negative drug interactions, worsening any adverse effects, including SCD [17].
The higher prevalence of AAS use among athletes, especially non-professionals, can be explained by their determination to achieve a perfect body and to improve performance and self-esteem. Indeed, the positive effects of AAS use are the increase of muscle mass, strength, energy and concentration, and the reduction of fat mass [57,58]. However, the use of anabolic-androgenic steroids has also many negative effects. Many of these are mild and transient (fluid retention, acne, agitation, gynecomastia, aggressiveness), but others are more serious and can damage multiple organs and functions, such as cardiovascular, reproductive, musculoskeletal, endocrine, renal, immunologic, and neuropsychiatric functions [2,57,58,59,60]. The cardiovascular system is one of the most affected by the side effects of AAS use. AAS use enhances vascular resistance and blood pressure, pro-inflammatory biomarker profile, and sympathetic tone alters serum lipoproteins and produces direct myocardial toxicity [53,61]. The adverse cardiovascular events reported are: impaired left ventricular function, arterial thrombosis, pulmonary embolism, and left ventricular hypertrophy, associated with myocytolysis and fibrosis [1]. It is reported that AAS abuse can promote cardiac tissue growth, leading to hypertrophic cardiomyopathy, followed by apoptotic cell death. This phenomenon is associated with ventricular remodeling, cardiomyopathy, myocardial infarction, and SCD and can explain how AAS may lead to cardiac death without coronary thrombosis or atherosclerosis [62,63]. AASs cause cardiac hypertrophy by a direct action on cardiac androgen receptors and these effects are directly proportional to the dose, time, and duration of administration [45]. Melchert and Welder proposed at least four hypothetical models explaining how AASs cause cardiovascular side effects. The atherogenic model concerns the alterations on lipoprotein serum levels caused by AASs, increasing the risk of atherosclerosis. The thrombosis model regards enhancing platelet aggregation and polycythemia that increase the risk of thrombus formation. The third model involves vasospasm caused by nitric oxide release induced by anabolic agents. The direct myocardial injury model concerns direct myocardial toxicity causing apoptosis, with increased collagen deposition, fibrosis, and altered microcirculation resulting in chronic ischemic damage. All of these mechanisms associate AAS use with a high risk of SCD [64,65].
A recent study showed that chronic nandrolone treatment with or without severe training causes a significant increase in beta–myosin heavy chain (β-MHC) gene expression, calcium/calmodulin-dependent protein kinaseIIδ (CaMKIIδ), and monoamine oxidase (MAO) activities in the heart tissue of male Wistar rats [66]. Cardiac hypertrophy has a genetic substrate too; ND, in adult rats, reduces cardiac contractile performance through enhancing β-MHC mRNA expressions, causing alterations of pressure-overload cardiac hypertrophy [67].
In the 9 cases of SCD, the most representative macroscopic alterations were cardiomegaly and left ventricular hypertrophy. Cardiomegaly was diagnosed by comparing the weight of the heart with the body weight and BMI of the subject [68,69,70]. Histologically, the most representative alterations were fibrosis and necrosis. These results are in agreement with what has been reported by many authors, according to whom myocardial necrosis and focal myocardial fibrosis, are highly significant alterations in the hearts of athletes who abuse AAS and may be responsible for atrioventricular conduction abnormalities and provide a substrate for the occurrence of potentially lethal arrhythmias and SCD [40,71,72,73]. It must be taken into account that, regardless of AAS abuse, increased cavity dimensions, wall thickness, and left ventricular mass are typical consequences of high-intensity exercise training and are included in the physiological cardiac remodeling of the “athlete’s heart”. A modest amount of fibrosis may be present in physiological cardiac remodeling associated with lifelong endurance training. This fibrosis and hypertrophy represent a substrate for arrhythmias [74,75]. When combined with exercise, AAS use has been shown to change physiological cardiac remodeling of the athlete to pathophysiological cardiac hypertrophy with an increased risk of life-threatening arrhythmias [1,76].
It is difficult to distinguish the etiology of these changes from histological findings alone, and it becomes essential to evaluate the subject’s clinical history and physical characteristics in all cases of sudden cardiac death in which AAS abuse is suspected. The physical phenotype of a male who abuses AASs includes some characteristics such as muscle hypertrophy, prominence striae above the pectoralis or biceps muscle, breast development in men (gynecomastia), testicular atrophy, and severe acne that may suggest AAS abuse [1,77]. In women, signs of AAS use also include hirsutism, deepening of the voice, and masculinization of secondary sexual characteristics [78,79].
Long-term use of AASs causes cardiac alterations affecting the conductive system, as demonstrated by subjects who have undergone signal-averaging electrocardiography (SAECG). SAECG is an inexpensive, safe, and highly reproducible technique that records low-amplitude electrical activity in the myocardium and provides information on the presence of a monomorphic TV substrate. SAECG performed on AAS users shows alterations in myocardial electrophysiology such as significantly longer QTc interval and greater QT dispersion, at rest and after moderate exercise, and attenuated heart rate recovery after exercise compared to subjects who do not use AASs. Abnormal SAECG indicates a re-entry mechanism for arrhythmias and, because sympathetic thrust during acute exercise lowers the ventricular fibrillation threshold, these individuals will be at increased risk of tachyarrhythmia and potential SCD following exercise [73,80,81]. Despite evidence linking the use of AAS abuse to SCD, reports in the literature are most likely underestimated due to the few autopsy data and because of the study of the pathophysiological mechanisms that lead to sudden cardiac death in subjects using AASs is severely limited [44,48,53]. In fact, information on the modalities and doses relating to the abuse of AASs is generally self-reported. Furthermore, most of the data in the literature on the effects of AAS administration derive from animal studies, as the administration of high doses of AASs in humans would be unethical, given the serious health risks [82].
Because of the high prevalence of AAS use among athletes, toxicological investigations are therefore fundamental in those cases of sudden death in subjects suspected of consuming AASs [83,84]. To date, there are still few studies published in the literature that correlates SCD in athletes with AAS use, highlighting the pathophysiological mechanisms that cause it and that are mostly based on experimental models derived from animal experiments [73,76,82,85,86,87,88,89,90,91]. It could be important to investigate new research fields to define the exact mechanism of action. For this reason, in recent years some studies have been carried out on miRNAs, a family of non-coding nucleotides that control gene expression and that appear to be related to numerous diseases. Mir-133a and mir-1, for example, appear to increase the risk of arrhythmia in the ischemic heart and may, in the future, play a role as prognostic biomarkers [25,92,93]. Nowadays, there are no studies in the literature that link the expression of miRNAs with SCD in AAS abusers.

5. Conclusions

Because of the high prevalence of AAS use among athletes, toxicological investigations are therefore fundamental in those cases of sudden death in which there is suspicion of AAS consumption. The cardiovascular system is one of the most affected by the side effects of AAS use. AAS use enhances vascular resistance and increases blood pressure, pro-inflammatory biomarker profile, sympathetic tone, alters serum lipoproteins, and produces direct myocardial toxicity. In agreement with the evidence in the literature, the most reported macroscopic heart changes reported in our review were cardiomegaly and hypertrophy, and the main histological changes were necrosis of myocardial tissue and foci of fibrosis. Hypertrophy, fibrosis, and necrosis represent a substrate for arrhythmias, especially when combined with exercise. AAS use has been shown to change physiological cardiac remodeling of athletes to pathophysiological cardiac hypertrophy with an increased risk of life-threatening arrhythmias. The evaluation of the parameters of electrocardiographic repolarization at rest and post-exercise, using SAECG, could provide diagnostic and prognostic information on the risk of cardiac arrhythmias and SCD in apparently healthy subjects who chronically use supraphysiological doses of AAS [27,81].
Since the pathophysiological mechanisms that lead to SCD in subjects who use AAS have not yet been fully clarified, the link between AAS abuse and SCD is probably underestimated, considering the few data in the literature.
Toxicological investigations, performed on different matrices, such as blood, urine, and hair, can confirm the use of AAS or other drugs that may have played a role in the death. A complete autopsy with histological and immunohistochemical studies, with a particular regard to the organs in which anabolic adverse events occur most frequently, is mandatory to evaluate the relationship between AAS use and SCD.
Given the young age of the subjects who usually use AASs and given the importance of the consequences related to their abuse, the identification of new tools to study AAS use, such as miRNAs, could be an important goal for the scientific community.
Nowadays, clinicians must pay attention to indicative signs of AAS use, considering those physical and epidemiological characteristics that can lead to the suspicion of abuse of these drugs to implement primary prevention measures of the serious adverse effects of AAS use. An interesting challenge would be to further investigate these findings to be able to use these biomarkers both to facilitate the post-mortem diagnosis of sudden deaths related to AAS abuse and as a screening method in living subjects to prevent fatal consequences.

Author Contributions

Conceptualization, M.S. and A.M.; methodology, F.A. and M.T.; software, G.C. and M.T.; validation, N.D.N., A.M., and M.S.; formal analysis, F.A., M.E., G.L.R. and I.R.; investigation, G.L.R.; resources, I.R., G.P. and M.T.; data curation, G.P., I.R. and M.T.; writing—original draft preparation, G.P. and M.E., writing—review and editing, G.P., I.R., and M.T.; visualization, F.A., and G.C.; supervision, A.L., A.M., and N.D.N.; project administration, A.L., A.M., and M.S. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Acknowledgments

The authors thank the Scientific Bureau of the University of Catania for language support.

Conflicts of Interest

The authors declare no conflict of interest.

Appendix A

Author (Year)Age (Years); Sex; Height; WeightBMIPersonal and Family Medical HistoryKind of Sport ActivityASS Reported Use—Time of AssumptionUse of Other DrugsCircumstance of DeathMacroscopic Heart FindingsHistological Heart FindingsToxicological AnalysisCause of Death
Campbell, S. E. et al. (1993)21; MNRAbsence of significant diseasesBodybuilderTestosterone; nandrolone—several monthsNRCollapse during a weight-lifting workout at the gym530 g—Marked left and right ventricular hypertrophy Extensive perivascular fibrosis of intramural coronary arteries—interstitial fibrosisNRUnspecified SCD
Dickerman, R. D. et al. (1995)20; M; 180 cm; 100.7 kg31.08No past or family history of cardiac diseaseBodybuilderMethenolone depot; veterinarian testosterone enanthate—just complete a 3-month cycleNRSudden witnessed death 515 g (0.51% of body weight)—Signs of concentric left ventricular hypertrophyMild atherosclerosisNRUnspecified SCD
Hausmann, R. et al. (1998)23; M; 192 cm; 94 kg25.50NRBodybuilderTestosterone cyclopentilpropionate; methenolone enanthate; mesterolone—9 monthsOther performance-enhancing drugs (liothyronine hydrochloride, clenbuterol hydrochloride)Found unconscious at home in his bed 500 g (0.53% of body weight)—Cardiac hypertrophy, right ventricle dilatation, focal induration of endocardiumEnlargement and nuclear polymorphism of the left ventricular muscle fibers. Disseminated focal necrosis and interstitial fibrosisUrine: Mesterolone, methandienone, testosterone, nandrolone, clenbuterolUnspecified SCD
Fineschi, V. et al. (2001)32; M; 189 cm; 90 kg25.20No history of diseaseBodybuilderTestosterone propionate; nandrolone—several monthsNRSudden loss of consciousness during a weight lifting workout450 g (0.50% of body weight)—Normal heart measures (14 × 14 × 4 cm)—Normal valves, endocardium, and coronary arteries—one grayish zone in the left ventricle myocardiumInfarct necrosis corresponding to the grayish zone—some foci of contraction band necrosis and fibrosisUrine: Metabolites of nandrolone, metabolites of stanozololSCD most likely related to adrenergic stress
29; M; 166 cm; 72 kg26.13His medical history was unremarkableBodybuilderNandrolone; stanozolol—several monthsNRFound unconscious at home in his bed 390 g (0.54% of body weight)—Normal heart measures (11 × 10 × 5 cm)—Normal valves, endocardium, and coronary arteries Occasional isolated myocardial cells with contraction band and segmentationUrine: Metabolites of nandrolone, metabolites of stanozololUnspecified SCD
Fineschi, V. et al. (2005)30; M; 178 cm; 90 kg28.41NRBodybuilderNandrolone decanoate—6 monthsUnspecified other drugsSudden collapse at home400g (0.44% of body weight) —Scattered fatty streaks in coronary arteriesFocal myocardial fibrosisUrine: Norandrosterone. Blood: nandroloneUnspecified SCD
Di Paolo, M. et al. (2007)29; M; 190 cm; 127 kg35.2No prior history of disease. No family history of cardiac disease under the age of 50BodybuilderHistory of use of unspecified AAS—unspecifiedNRSudden loss of consciousness during the first minutes of a spin bike lesson490 g (0.39% of body weight)—Normal hearth wall thickness, normal valve, normal coronary arteriesSevere epicardial interstitial fibrosis, small vessel diseaseNegativeUnspecified SCD
27; M; 190 cm; 100 kg25.8No prior history of disease. No family history of cardiac disease under the age of 50BodybuilderHistory of use of unspecified AAS—unspecifiedNRSudden illness while he was at a night club360 g (0.36% of body weight)—Normal hearth wall thickness, normal valve, normal coronary arteriesMild focal epicardial interstitial fibrosis, small vessel diseaseUrine: Stanozolol, testosteroneUnspecified SCD
37; F; 161 cm; 71 kg27.4No prior history of disease. No family history of cardiac disease under the age of 50Bodybuilder and weight lifterHistory of use of unspecified AAS—unspecifiedNRFound dead in her car310 g (0.44% of body weight) —Normal hearth wall thickness, normal valve, normal coronary arteriesModerate focal epicardial interstitial fibrosis, small vessel diseaseNegativeUnspecified SCD
31; M; 175 cm; 79 kg25.8No prior history of disease. No family history of cardiac disease under the age of 50BodybuilderHistory of use of unspecified AAS—unspecifiedNRFound dead in his bedroom: alive 7 h before400 g (0.51% of body weight)—Normal hearth wall thickness, normal valve, normal coronary arteriesModerate epicardial interstitial fibrosis, small vessel diseaseUrine: StanozololUnspecified SCD
Fanton, L. et al. (2009)19; MNRNo history of cardiac diseaseWeight lifterHistory of use of unspecified AAS—unspecifiedNRSD during training360 g—Left ventricle apoplexyMultiple focal areas of necrosis, myolysis, scarring fibrosisNRUnspecified SCD
22; MNRNo history of cardiac diseasePE teacherHistory of use of unspecified AAS—unspecifiedNRSD during training520 g—Left ventricle apoplexyMultiple focal areas of necrosis, myolysis, scarring fibrosisNRUnspecified SCD
25; MNRNo history of cardiac diseaseBodybuilderHistory of use of unspecified AAS—unspecifiedNRSD during training460 g—Disseminated myocarditisMultiple focal areas of necrosis, myolysis, scarring fibrosisNRUnspecified SCD
28; MNRNo history of cardiac diseaseSoccer playerHistory of use of unspecified AAS—unspecifiedNRSD during training380 g—Disseminated myocarditisMultiple focal areas of necrosis, myolysis, scarring fibrosisNRUnspecified SCD
54; MNRNo history of cardiac diseaseMarathon runnerHistory of use of unspecified AAS—unspecifiedNRSD during training410 g—Coronary thrombosis and dilated cardiomyopathymultiple focal areas of necrosis, myolysis, scarring fibrosisNRUnspecified SCD
48; MNRNo history of cardiac diseaseMarathon runnerHistory of use of unspecified AAS—unspecifiedNRSD during training430 g—Left ventricle hypertrophyMultiple focal areas of necrosis, myolysis, scarring fibrosisNRUnspecified SCD
Thiblin, I. et al. (2009)29; F; 172 cm; 76 kg25.7No history of diseaseFitness athleteHistory of use of unspecified AAS—unspecifiedUnspecified other drugsFound naked in a prone position on the floor beside her bed, with a pillow partly under her body331 g (0.44% of body weight)—Normal heart measures—Normal coronary arteries, with an isolated flat area of fatty thickening in the proximal part of the left anterior descending (LAD) coronary artery.Lymphocytic infiltration around several middle-sized and small intramural vessels—minimal myocardial necrosisBlood: ephedrine, norephedrine. Urine: testosterone, metabolites of stanozolol, boldenoneSudden cardiac arrhythmia, possibly related to the combination of an otherwise unspecified inflammatory process in the heart and the acute influence of ASS and ephedrine
Montisci, M. et al. (2012)32; M; 180 cm; 110 kg33.95NRBodybuilderHistory of use of unspecified AAS—7 years (recently withdraw)NRFound dead at home in his bed 450 g (0.41% of body weight)—11 × 9.5 cm—cardiomegaly, concentric left ventricular hypertrophy, normal valve, normal coronary arteriesHypertrophic myocytes, focal disarray, interstitial and replacement fibrosis, foci of lymphoplasma cellular infiltrates (CD3+), with edema and patchy necrosisNegativeConcentric left ventricular hypertrophy, focal acute myocarditis.
32; M; 178 cm; 94 kg29.67At last screening, nonspecific repolarization changes were found at ECGCyclerHistory of use of unspecified AAS—several yearsNRSD after a dentistry visit580 g (0.62% of body weight)—12.5 × 11 cm—Cardiomegaly, hypertrophy, biventricular dilatation, normal valve, non-obstructive LAD stenosisHypertrophic myocytes, foci of necrosis, replacement fibrosis, LAD 50% stenosis, fibrofatty replacementNegativeInflammatory dilated cardiomyopathy with subacute-chronic stages, hemorrhagic pulmonary infarction
25; M, 185 cm; 125 kg36.52An ECG performed 5y before death was normalBodybuilderCircumstantial finding of unspecified use of AAS—unspecifiedUnspecified other performance-enhancing drugs SD while sleeping390 g (0.31% of body weight)—10.5 × 9.5 cm—normal hearth wall thickness, normal valve, normal coronary arteriesInflammatory infiltrate, myocyte necrosisUrine: Testosterone, epitestosterone, nortestosteroneEosinophilic myocarditis
Lusetti, M. et al. (2015)39 (mean age); M (All 6 cases)NRNRNRHistory of use of unspecified AAS—unspecifiedNRSudden unwitnessed deathNormal hearth wall thickness, normal valve, normal coronary arteries. In one case: 490 g (0.54% of body weight)Interstitial fibrosis (6 cases); perivascular fibrosis (4 cases); perineural fibrosis within the left ventricle (2 cases); fibroadipous metaplasia (2 cases); contraction band necrosis (2 cases); Myocyte segmentation (2 cases); Intercalated disc widening (2 cases); myocyte hypertrophy (3 cases); coronary intimal and media thickening (4 cases)Blood: Ethanol (1 case). Urine and hair: nandrolone (3 cases), Testosterone (3 cases)Sudden cardiac arrhythmia
Lichtenfeld, J. et al. (2016)13; MNRNo prior history of disease. An episode of syncope with exertion 1 week before cardiac arrest. No family history of sudden death, hypertrophic cardiomyopathy, or heart rhythm abnormalitiesSprinterPhysical Phenotype suggesting AAS useNRSudden cardiac arrest while performing timed wind sprints at a competitive sports camp465 g—Cardiomegaly, marked LV HypertrophyFoci of myofibrillar disarray, the proliferation of fibroblasts consistent with early fibrosis, and enlarged myofibers with the heterogeneity of nuclear size including “box-car” nucleiNRSudden cardiac arrest followed by brain death
Lusetti, M. et al. (2018)32; MNRNo “officially” medically prescribed drug treatment at the time of death.NRHistory of use of unspecified AAS—unspecifiedNRunspecified SD390 g—Left ventricular hypertrophyMyocardial fibrosisUrine: Nandrolone, Testosterone. Blood: Methadone, Citalopram, Clozapine, Venlafaxine, Lorazepam, Phenobarbital, THCUnspecified SCD
32; MNRNo “officially” medically prescribed drug treatment at the time of death.NRHistory of use of unspecified AAS—unspecifiedNRunspecified SD360 gFatty streaks, intima, and media thickening within the coronary arteriesUrine: Boldenone, Clomiphene, Methenolone, Oxandrolone, Stanozolol. Blood: Lorazepam, THCUnspecified SCD
33; MNRNo “officially” medically prescribed drug treatment at the time of death.NRHistory of use of unspecified AAS—unspecifiedNRunspecified SD425 g—Left ventricular hypertrophyMyocyte necrosisUrine: Testosterone. Blood: Methadone, CocaineUnspecified SCD
39; MNRNo “officially” medically prescribed drug treatment at the time of death.NRHistory of use of unspecified AAS—unspecifiedNRunspecified SD480 g—Left and right ventricular hypertrophyMyocyte necrosis, Myocardial fibrosisUrine: Nandrolone. Blood: Morphine, THCUnspecified SCD
29; MNRNo “officially” medically prescribed drug treatment at the time of death.NRHistory of use of unspecified AAS—unspecifiedNRunspecified SD340 gNRUrine: Nandrolone, Testosterone. Blood: morphine, THC, EthanolUnspecified SCD
Hernandez-Guerra, A. I. et al. (2019)24; M; 178 cm; 85 Kg26.8No past or family history of cardiac disease. One episode of precordial pain some months before.NRstanozolol, testosterone, mesterolone, nandrolone—6 monthstamoxifenSudden death at home420 g (0.49% of body weight)—Cardiomegaly, Normal ventricular thickness, >75% Stenosis of the left main trunk and the LAD, areas of scarring located at the intersection between the posterior wall and the posterior third of the septumAcute myocardial infarction, myocytes hypertrophy, small intramyocardial vessel diseaseBlood: Ethanol, Stanozolol, NandroloneAcute myocardial infarction

References

  1. Hernández-Guerra, A.I.; Tapia, J.; Menéndez-Quintanal, L.M.; Lucena, J.S. Sudden cardiac death in anabolic androgenic steroids abuse: Case report and literature review. For. Sci. Res. 2019, 4, 267–273. [Google Scholar] [CrossRef] [PubMed]
  2. Piacentino, D.; D Kotzalidis, G.; Del Casale, A.; Rosaria Aromatario, M.; Pomara, C.; Girardi, P.; Sani, G. Anabolic-androgenic steroid use and psychopathology in athletes. A systematic review. Curr. Neuropharmacol. 2015, 13, 101–121. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Al-harbi, F.F.; Gamaleddin, I.; Alsubaie, E.G.; Al-Surimi, K.M. Prevalence and Risk Factors Associated with Anabolic-androgenic Steroid Use: A Cross-sectional Study among Gym Users in Riyadh, Saudi Arabia. Oman Med. J. 2020, 35, e110. [Google Scholar] [CrossRef] [PubMed]
  4. Bhasin, S.; Cunningham, G.R.; Hayes, F.J.; Matsumoto, A.M.; Snyder, P.J.; Swerdloff, R.S.; Montori, V.M. Testosterone therapy in men with androgen deficiency syndromes: An endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 2010, 95, 2536–2559. [Google Scholar] [CrossRef] [PubMed]
  5. Nieschlag, E. Current topics in testosterone replacement of hypogonadal men. Best Pract. Res. Clin. Endocrinol. Metab. 2015, 29, 77–90. [Google Scholar] [CrossRef] [PubMed]
  6. Carrasquillo, R.; Chu, K.; Ramasamy, R. Novel therapy for male hypogonadism. Curr. Urol. Rep. 2018, 19, 63. [Google Scholar] [CrossRef]
  7. Orr, R.; Singh, M.F. The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders. Drugs 2004, 64, 725–750. [Google Scholar] [CrossRef] [PubMed]
  8. Wu, C.; Kovac, J.R. Novel uses for the anabolic androgenic steroids nandrolone and oxandrolone in the management of male health. Curr. Urol. Rep. 2016, 17, 72. [Google Scholar] [CrossRef] [PubMed]
  9. Frati, P.; P Busardo, F.; Cipolloni, L.; De Dominicis, E.; Fineschi, V. Anabolic androgenic steroid (AAS) related deaths: Autoptic, histopathological and toxicological findings. Curr. Neuropharmacol. 2015, 13, 146–159. [Google Scholar] [CrossRef] [Green Version]
  10. Pereira, E.; Moyses, S.J.; Ignácio, S.A.; Mendes, D.K.; Da Silva, D.S.; Carneiro, E.; Johann, A.C.B.R. Anabolic steroids among resistance training practitioners. PLoS ONE 2019, 14, e0223384. [Google Scholar]
  11. Reyes-Vallejo, L. Current use and abuse of anabolic steroids. Actas Urol. Esp. 2020, 44, 309–313. [Google Scholar] [CrossRef]
  12. Fineschi, V.; Neri, M.; Di Donato, S.; Pomara, C.; Riezzo, I.; Turillazzi, E. An immunohistochemical study in a fatality due to ovarian hyperstimulation syndrome. Int. J. Legal Med. 2006, 120, 293–299. [Google Scholar] [CrossRef]
  13. Sagoe, D.; Molde, H.; Andreassen, C.S.; Torsheim, T.; Pallesen, S. The global epidemiology of anabolic-androgenic steroid use: A meta-analysis and meta-regression analysis. Ann. Epidemiol. 2014, 24, 383–398. [Google Scholar] [CrossRef] [Green Version]
  14. Kanayama, G.; Pope Jr, H.G. History and epidemiology of anabolic androgens in athletes and non-athletes. Mol. Cell Endocrinol. 2018, 464, 4–13. [Google Scholar] [CrossRef]
  15. Kicman, A.T. Pharmacology of anabolic steroids. Br. J. Pharmacol. 2008, 154, 502–521. [Google Scholar] [CrossRef]
  16. Bertozzi, G.; Salerno, M.; Pomara, C.; Sessa, F. Neuropsychiatric and behavioral involvement in AAS abusers. A literature review. Medicina 2019, 55, 396. [Google Scholar] [CrossRef] [Green Version]
  17. Sessa, F.; Salerno, M.; Cipolloni, L.; Bertozzi, G.; Messina, G.; Di Mizio, G.; Pomara, C. Anabolic-androgenic steroids and brain injury: miRNA evaluation in users compared to cocaine abusers and elderly people. Aging 2020, 12, 15314. [Google Scholar] [CrossRef] [PubMed]
  18. Agriesti, F.; Tataranni, T.; Pacelli, C.; Scrima, R.; Laurenzana, I.; Ruggieri, V.; Sani, G. Nandrolone induces a stem cell-like phenotype in human hepatocarcinoma-derived cell line inhibiting mitochondrial respiratory activity. Sci. Rep. 2020, 10, 1–17. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  19. Bertozzi, G.; Sessa, F.; Maglietta, F.; Cipolloni, L.; Salerno, M.; Fiore, C.; Pomara, C. Immunodeficiency as a side effect of anabolic androgenic steroid abuse: A case of necrotizing myofasciitis. For. Sci. Med. Pathol. 2019, 15, 616–621. [Google Scholar] [CrossRef] [PubMed]
  20. Bertozzi, G.; Sessa, F.; Albano, G.D.; Sani, G.; Maglietta, F.; Roshan, M.H.; Salerno, M. The role of anabolic androgenic steroids in disruption of the physiological function in discrete areas of the central nervous system. Mol. Neurobiol. 2018, 55, 5548–5556. [Google Scholar] [CrossRef]
  21. Pomara, C.; Neri, M.; Bello, S.; Fiore, C.; Riezzo, I.; Turillazzi, E. Neurotoxicity by synthetic androgen steroids: Oxidative stress, apoptosis, and neuropathology: A review. Curr. Neuropharmacol. 2015, 13, 132–145. [Google Scholar] [CrossRef] [Green Version]
  22. Pomara, C.; Barone, R.; Marino Gammazza, A.; Sangiorgi, C.; Barone, F.; Pitruzzella, A.; Locorotondo, N.; Di Gaudio, F.; Salerno, M.; Maglietta, F.; et al. Effects of nandrolone stimulation on testosterone biosynthesis in leydig cells. J. Cell Physiol. 2016, 231, 1385–1391. [Google Scholar] [CrossRef] [Green Version]
  23. Albano, G.D.; Sessa, F.; Messina, A.; Monda, V.; Bertozzi, G.; Maglietta, F.; Giugliano, P.; Vacchiano, G.; Gabriella, M.; Salerno, M. AAS and organs damage: A focus on Nandrolone effects. Acta Med. Mediter. 2017, 6, 939–946. [Google Scholar]
  24. Joukar, S.; Yoosefnia, M.; Naderi-Boldaji, V.; Nasri, H.; Rafie, F. Heart reaction to nandrolone decanoate plus two different intensities of endurance exercise: Electrocardiography and stereological approach. Addict. Health 2018, 10, 180. [Google Scholar]
  25. Wadthaisong, M.; Witayavanitkul, N.; Bupha-Intr, T.; Wattanapermpool, J.; De Tombe, P.P. Chronic high-dose testosterone treatment: Impact on rat cardiac contractile biology. Physiol. Rep. 2019, 7, e14192. [Google Scholar] [CrossRef]
  26. Climstein, M.; O’Shea, P.; Adams, K.J.; DeBeliso, M. The effects of anabolic-androgenic steroids upon resting and peak exercise left ventricular heart wall motion kinetics in male strength and power athletes. J. Sci. Med. Sport 2003, 6, 387–397. [Google Scholar] [CrossRef]
  27. Pomara, C.; D’Errico, S.; Riezzo, I.; De Cillis, G.P.; Fineschi, V. Sudden cardiac death in a child affected by Prader-Willi syndrome. Int. J. Legal Med. 2005, 119, 153–157. [Google Scholar] [CrossRef]
  28. Chatwin, C.; Measham, F.; O’Brien, K.; Sumnall, H. New drugs, new directions? Research priorities for new psychoactive substances and human enhancement drugs. Int. J. Drug Policy 2017, 40, 1–5. [Google Scholar] [CrossRef]
  29. Nieschlag, E.; Vorona, E. Mechanisms in endocrinology: Medical consequences of doping with anabolic androgenic steroids: Effects on reproductive functions. Eur. J. Endocrinol. 2015, 173, 47–58. [Google Scholar] [CrossRef]
  30. Ahlgrim, C.; Guglin, M. Anabolics and cardiomyopathy in a bodybuilder: Case report and literature review. J. Card Fail. 2009, 15, 496–500. [Google Scholar] [CrossRef]
  31. Angoorani, H.; Narenjiha, H.; Tayyebi, B.; Ghassabian, A.; Ahmadi, G.; Assari, S. Amphetamine use and its associated factors in body builders: A study from Tehran, Iran. Arch. Med. Sci. 2012, 8, 362. [Google Scholar] [CrossRef]
  32. Bilard, J.; Ninot, G.; Hauw, D. Motives for illicit use of doping drugs among athletes calling a national antidoping phone-help service: An exploratory study. Subst. Use Misuse 2011, 46, 359–367. [Google Scholar] [CrossRef]
  33. Sagoe, D.; McVeigh, J.; Bjørnebekk, A.; Essilfie, M.S.; Andreassen, C.S.; Pallesen, S. Polypharmacy among anabolic-androgenic steroid users: A descriptive metasynthesis. Subst. Abuse Treat. Prev. Policy 2015, 10, 12. [Google Scholar] [CrossRef] [Green Version]
  34. Wong, C.X.; Brown, A.; Lau, D.H.; Chugh, S.S.; Albert, C.M.; Kalman, J.M.; Sanders, P. Epidemiology of sudden cardiac death: Global and regional perspectives. Heart Lung Circ. 2019, 28, 6–14. [Google Scholar] [CrossRef] [Green Version]
  35. Doolan, A.; Semsarian, C.; Langlois, N. Causes of sudden cardiac death in young Australians. Med. J. Aust. 2004, 180, 110–112. [Google Scholar] [CrossRef]
  36. Muller, D.; Agrawal, R.; Arntz, H.R. How sudden is sudden cardiac death. Circulation 2006, 114, 1146–1150. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  37. Campbell, S.E.; Farb, A.; Weber, K.T. Pathologic remodeling of the myocardium in a weightlifter taking anabolic steroids case report. Blood Press 1993, 2, 213–216. [Google Scholar] [CrossRef]
  38. Dickerman, R.D.; Schaller, F.; Prather, I.; McConathy, W.J. Sudden cardiac death in a 20-year-old bodybuilder using anabolic steroids. Cardiology 1995, 86, 172–173. [Google Scholar] [CrossRef]
  39. Hausmann, R.; Hammer, S.; Betz, P. Performance enhancing drugs (doping agents) and sudden death–a case report and review of the literature. Int. J. Legal Med. 1998, 111, 261–264. [Google Scholar] [CrossRef]
  40. Fineschi, V.; Baroldi, G.; Monciotti, F.; Reattelli, L.P.; Turillazzi, E. Anabolic steroid abuse and cardiac sudden death: A pathologic study. Arch. Pathol. Lab. Med. 2001, 125, 253–255. [Google Scholar]
  41. Fineschi, V.; Riezzo, I.; Centini, F.; Silingardi, E.; Licata, M.; Beduschi, G.; Karch, S.B. Sudden cardiac death during anabolic steroid abuse: Morphologic and toxicologic findings in two fatal cases of bodybuilders. Int. J. Legal Med. 2007, 121, 48–53. [Google Scholar] [CrossRef]
  42. Di Paolo, M.; Agozzino, M.; Toni, C.; Luciani, A.B.; Molendini, L.; Scaglione, M.; Arbustini, E. Sudden anabolic steroid abuse-related death in athletes. Int. J. Cardiol. 2007, 114, 114–117. [Google Scholar] [CrossRef] [PubMed]
  43. Fanton, L.; Belhani, D.; Vaillant, F.; Tabib, A.; Gomez, L.; Descotes, J.; Timour, Q. Heart lesions associated with anabolic steroid abuse: Comparison of post-mortem findings in athletes and norethandrolone-induced lesions in rabbits. Exp. Toxicol. Pathol. 2009, 61, 317–323. [Google Scholar] [CrossRef]
  44. Thiblin, I.; Mobini-Far, H.; Frisk, M. Sudden unexpected death in a female fitness athlete, with a possible connection to the use of anabolic androgenic steroids (AAS) and ephedrine. For. Sci. Int. 2009, 184, 7–11. [Google Scholar] [CrossRef]
  45. Montisci, M.; El Mazloum, R.; Cecchetto, G.; Terranova, C.; Ferrara, S.D.; Thiene, G.; Basso, C. Anabolic androgenic steroids abuse and cardiac death in athletes: Morphological and toxicological findings in four fatal cases. Forensic Sci. Int. 2012, 217, 13–18. [Google Scholar] [CrossRef]
  46. Lusetti, M.; Licata, M.; Silingardi, E.; Bonetti, L.R.; Palmiere, C. Pathological changes in anabolic androgenic steroid users. J. For. Leg. Med. 2015, 33, 101–104. [Google Scholar] [CrossRef] [PubMed]
  47. Lichtenfeld, J.; Deal, B.J.; Crawford, S. Sudden cardiac arrest following ventricular fibrillation attributed to anabolic steroid use in an adolescent. Cardiol. Young 2016, 26, 996–998. [Google Scholar] [CrossRef]
  48. Lusetti, M.; Licata, M.; Silingardi, E.; Bonsignore, A.; Palmiere, C. Appearance/image- and performance-enhancing drug users: A forensic approach. Am. J. For. Med. Pathol. 2018, 39, 325–329. [Google Scholar] [CrossRef]
  49. Narayan, S.M.; Wang, P.J.; Daubert, J.P. New concepts in sudden cardiac arrest to address an intractable epidemic: JACC state-of-the-art review. J. Am. Coll. Cardiol. 2019, 73, 70–88. [Google Scholar] [CrossRef]
  50. Wasfy, M.M.; Hutter, A.M.; Weiner, R.B. Sudden cardiac death in athletes. Methodist DeBakey Cardiovasc. J. 2016, 12, 76. [Google Scholar] [CrossRef] [Green Version]
  51. Harmon, K.G.; Asif, I.M.; Klossner, D.; Drezner, J.A. Incidence of sudden cardiac death in National Collegiate Athletic Association athletes. Circulation 2011, 123, 1594–1600. [Google Scholar] [CrossRef] [Green Version]
  52. Ackerman, M.; Atkins, D.L.; Triedman, J.K. Sudden cardiac death in the young. Circulation 2016, 133, 1006–1026. [Google Scholar] [CrossRef] [Green Version]
  53. Sheppard, M.N. Aetiology of sudden cardiac death in sport: A histopathologist’s perspective. Br. J. Sports Med. 2012, 46, i15–i21. [Google Scholar] [CrossRef]
  54. Wolk, R. Arrhythmogenic mechanisms in left ventricular hypertrophy. Europace 2000, 2, 216–223. [Google Scholar] [CrossRef]
  55. Aro, A.L.; Reinier, K.; Phan, D.; Teodorescu, C.; Uy-Evanado, A.; Nichols, G.A.; Chugh, S.S. Left-ventricular geometry and risk of sudden cardiac arrest in patients with preserved or moderately reduced left-ventricular ejection fraction. Europace 2017, 19, 1146–1152. [Google Scholar] [CrossRef] [PubMed]
  56. Montagnana, M.; Lippi, G.; Franchini, M.; Banfi, G.; Guidi, G.C. Sudden cardiac death in young athletes. Intern. Med. 2008, 47, 1373–1378. [Google Scholar] [CrossRef] [Green Version]
  57. Smit, D.L.; De Hon, O.; Venhuis, B.J.; Den Heijer, M.; De Ronde, W. Baseline characteristics of the HAARLEM study: 100 male amateur athletes using anabolic androgenic steroids. Scand. J. Med. Sci. Sports 2020, 30, 531–539. [Google Scholar] [CrossRef]
  58. De Ronde, W.; Smit, D.L. Anabolic androgenic steroid abuse in young males. Endocronol. Connect. 2020, 9, 102–111. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  59. Salerno, M.; Cascio, O.; Bertozzi, G.; Sessa, F.; Messina, A.; Monda, V.; Pomara, C. Anabolic androgenic steroids and carcinogenicity focusing on Leydig cell: A literature review. Oncotarget 2018, 9, 19415. [Google Scholar] [CrossRef] [Green Version]
  60. Monda, V.; Salerno, M.; Sessa, F.; Bernardini, R.; Valenzano, A.; Marsala, G.; Zammit, C.; Avola, R.; Carotenuto, M.; Messina, G.; et al. Functional changes of orexinergic reaction to psychoactive substances. Mol. Neurobiol. 2018, 55, 6362–6368. [Google Scholar] [CrossRef]
  61. Rothman, R.D.; Weiner, R.B.; Pope, H.; Kanayama, G.; Hutter, A.M.; Fifer, M.A.; Baggish, A.L. Anabolic androgenic steroid induced myocardial toxicity: An evolving problem in an ageing population. BMJ Case Rep. 2011. [Google Scholar] [CrossRef] [PubMed]
  62. Youssef, M.Y.; Alqallaf, A.; Abdella, N. Anabolic androgenic steroid-induced cardiomyopathy, stroke and peripheral vascular disease. BMJ Case Rep. 2011. [Google Scholar] [CrossRef] [Green Version]
  63. Baggish, A.L.; Weiner, R.B.; Kanayama, G.; Hudson, J.I.; Lu, M.T.; Hoffmann, U.; Pope, H.G., Jr. Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation 2017, 135, 1991–2002. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  64. Melchert, R.B.; Welder, A.A. Cardiovascular effects of androgenic-anabolic steroids. Med. Sci. Sports Exerc. 1995, 27, 1252–1262. [Google Scholar] [CrossRef]
  65. Monda, V.; Salerno, M.; Fiorenzo, M.; Villano, I.; Viggiano, A.; Sessa, F.; Triggiani, A.I.; Cibelli, G.; Valenzano, A.; Marsala, G.; et al. Role of sex hormones in the control of vegetative and metabolic functions of middle-aged women. Front. Physiol. 2017, 8, 773. [Google Scholar] [CrossRef] [Green Version]
  66. Shirpoor, A.; Heshmatian, B.; Tofighi, A.; Eliasabad, S.N.; Kheradmand, F.; Zerehpoosh, M. Nandrolone administration with or without strenuous exercise increases cardiac fatal genes overexpression, calcium/calmodulin-dependent protein kinaseiiδ, and monoamine oxidase activities and enhances blood pressure in adult wistar rats. Gene 2019, 697, 131–137. [Google Scholar] [CrossRef]
  67. Vanderheyden, M.; Mullens, W.; Delrue, L.; Goethals, M.; De Bruyne, B.; Wijns, W.; Geelen, P.; Verstreken, S.; Wellens, F.; Bartunek, J. Myocardial gene expression in heart failure patients treated with cardiac resynchronization therapy responders versus nonresponders. J. Am. Coll. Cardiol. 2008, 51, 129–136. [Google Scholar] [CrossRef] [Green Version]
  68. Kitzman, D.W.; Scholz, D.G.; Hagen, P.T.; Ilstrup, D.M.; Edwards, W.D. Age-related changes in normal human hearts during the first 10 decades of life. Part II (maturity): A quantitative anatomic study of 765 specimens from subjects 20 to 99 years old. Mayo Clin. Proc. 1988, 63, 137–146. [Google Scholar] [CrossRef]
  69. Mandal, R.; Loeffler, A.G.; Salamat, S.; Fritsch, M.K. Organ weight changes associated with body mass index determined from a medical autopsy population. Am. J. For. Med. Pathol. 2012, 33, 382–389. [Google Scholar] [CrossRef]
  70. Neri, M.; Riezzo, I.; Pomara, C.; Schiavone, S.; Turillazzi, E. Oxidative-nitrosative stress and myocardial dysfunctions in sepsis: Evidence from the literature and postmortem observations. Mediat. Inflamm. 2016, 2016, 3423450. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  71. Kennedy, M.C.; Lawrence, C. Anabolic steroid abuse and cardiac death. Med. J. Aust. 1993, 158, 346–348. [Google Scholar] [CrossRef]
  72. Sullivan, M.L.; Martinez, C.M.; Gennis, P.; Gallagher, E.J. The cardiac toxicity of anabolic steroids. Prog. Cardiovasc. Dis. 1998, 41, 1–15. [Google Scholar] [CrossRef]
  73. Sculthorpe, N.; Grace, F.; Jones, P.; Davies, B. Evidence of altered cardiac electrophysiology following prolonged androgenic anabolic steroid use. Cardiovasc. Toxicol. 2010, 10, 239–243. [Google Scholar] [CrossRef] [Green Version]
  74. Carbone, A.; D’Andrea, A.; Riegler, L.; Scarafile, R.; Pezzullo, E.; Martone, F.; America, R.; Liccardo, B.; Galderisi, M.; Bossone, E.; et al. Cardiac damage in athlete’s heart: When the “supernormal” heart fails! World J. Cardiol. 2017, 9, 470. [Google Scholar] [CrossRef]
  75. Papamitsou, T.; Barlagiannis, D.; Papaliagkas, V.; Kotanidou, E.; Dermentzopoulou-Theodoridou, M. Testosterone-induced hypertrophy, fibrosis and apoptosis of cardiac cells–an ultrastructural and immunohistochemical study. Med. Sci. Monit. 2011, 17, 266. [Google Scholar] [CrossRef] [Green Version]
  76. Riezzo, I.; Di Paolo, M.; Neri, M.; Bello, S.; Cantatore, S.; D’Errico, S.; Dinucci, D.; Parente, R.; Pomara, C.; Rabozzi, R.; et al. Anabolic steroid-and exercise-induced cardio-depressant cytokines and myocardial β1 receptor expression in CD1 mice. Curr. Pharm. Biotechnol. 2011, 12, 275–284. [Google Scholar] [CrossRef] [PubMed]
  77. Kanayama, G.; Hudson, J.I.; Pope, H.G., Jr. Anabolic-androgenic steroid use and body image in men: A growing concern for clinicians. Psychother. Psychosom. 2020, 89, 65–73. [Google Scholar] [CrossRef]
  78. Pope, H.; Brower, K.J. Treatment of anabolic-androgenic steroid related disorders. In The American Psychiatric Publishing Textbook of Substance Abuse Treatment; American Psychiatric Publishing: Washington, DC, USA, 2008; pp. 237–246. [Google Scholar]
  79. Sessa, F.; Salerno, M.; Bertozzi, G.; Cipolloni, L.; Messina, G.; Aromatario, M.; Polo, L.; Turillazzi, E.; Pomara, C. miRNAs as novel biomarkers of chronic kidney injury in anabolic-androgenic steroid users: An experimental study. Front. Pharmacol. 2020, 11, 1454. [Google Scholar] [CrossRef]
  80. Gatzoulis, K.A.; Arsenos, P.; Trachanas, K.; Dilaveris, P.; Antoniou, C.; Tsiachris, D.; Tousoulis, D. Signal-averaged electrocardiography: Past, present, and future. J. Arrhythm. 2018, 34, 222–229. [Google Scholar] [CrossRef] [PubMed]
  81. Maior, A.S.; Menezes, P.; Pedrosa, R.C.; Carvalho, D.P.; Soares, P.P.; Nascimento, J.H.M. Abnormal cardiac repolarization in anabolic androgenic steroid users carrying out submaximal exercise testing. Clin. Exp. Pharmacol. Physiol. 2010, 37, 1129–1133. [Google Scholar] [CrossRef] [PubMed]
  82. Ozdemir, O.; Bozkurt, I.; Ozdemir, M.; Yavuz, O. Side effect of metenolone enanthate on rats heart in puberty: Morphometrical study. Exp. Toxicol. Pathol. 2013, 65, 745–750. [Google Scholar] [CrossRef] [PubMed]
  83. Strano-Rossi, S.; Fiore, C.; Chiarotti, M.; Centini, F. Analytical techniques in androgen anabolic steroids (AASs) analysis for antidoping and forensic purposes. Mini Rev. Med. Chem. 2011, 11, 451–458. [Google Scholar] [CrossRef]
  84. Sessa, F.; Franco, S.; Picciocchi, E.; Geraci, D.; Chisari, M.G.; Marsala, G.; Polito, A.N.; Sorrentino, M.; Tripi, G.; Salerno, M.; et al. Addictions substance free during lifespan. Acta Med. Mediter. 2018, 34, 2081–2087. [Google Scholar]
  85. Moacir, M.; Silva-Neto, J.A.; Neto, O.B. Acute interruption of treatment with nandrolone decanoate is not sufficient to reverse cardiac autonomic dysfunction and ventricular repolarization disturbances in rats. Steroids 2018, 132, 12–17. [Google Scholar]
  86. Olivares, E.L.; Silveira, A.L.; Fonseca, F.V.; Silva-Almeida, C.; Côrtes, R.S.; Pereira-Junior, P.P.; Nascimento, J.H.M.; Reis, L.C. Administration of an anabolic steroid during the adolescent phase changes the behavior, cardiac autonomic balance and fluid intake in male adult rats. Physiol. Behav. 2014, 126, 15–24. [Google Scholar] [CrossRef] [Green Version]
  87. Marocolo, M.; Maior, A.S.; Katayama, P.L.; Mota, G.R.D.; Neto, O.B.; Lauria, A.D.A.; Santos, E.L. Anabolic steroid treatment induces cardiac autonomic dysfunction in rats: Time-course of heart rate variability. Am. J. Biomed. Eng. 2013, 3, 54–62. [Google Scholar]
  88. Tanno, A.P.; Cunha, T.S.; Fernandes, T.; Guzzoni, V.; da Silva, C.A.; de Oliveira, E.M.; Costa Sampaio Moura, M.J.; Marcondes, F.K. Effects of nandrolone and resistance training on the blood pressure, cardiac electrophysiology, and expression of atrial β-adrenergic receptors. Life Sci. 2013, 92, 1029–1035. [Google Scholar]
  89. Medei, E.; Marocolo, M.; de Carvalho Rodrigues, D.; Arantes, P.C.; Takiya, C.M.; Silva, J.; Rondinelli, E.; dos Santos Goldenberg, R.C.; Campos de Carvalho, A.C.; Nascimento, J.H.M. Chronic treatment with anabolic steroids induces ventricular repolarization disturbances: Cellular, ionic and molecular mechanism. J. Mol. Cell Cardiol. 2010, 49, 165–175. [Google Scholar] [CrossRef]
  90. Phillis, B.D.; Abeywardena, M.Y.; Adams, M.J.; Kennedy, J.A.; Irvine, R.J. Nandrolone potentiates arrhythmogenic effects of cardiac ischemia in the rat. Toxicol. Sci. 2007, 99, 605–611. [Google Scholar] [CrossRef] [PubMed]
  91. Binayi, F.; Joukar, S.; Najafipour, H.; Karimi, A.; Abdollahi, F.; Masumi, Y. The effects of nandrolone decanoate along with prolonged low-intensity exercise on susceptibility to ventricular arrhythmias. Cardiovasc. Toxicol. 2016, 16, 23–33. [Google Scholar] [CrossRef]
  92. Sessa, F.; Salerno, M.; Di Mizio, G.; Bertozzi, G.; Messina, G.; Tomaiuolo, B.; Pisanelli, D.; Maglietta, F.; Ricci, P.; Pomara, C. Anabolic androgenic steroids: Searching new molecular biomarkers. Front. Pharmacol. 2018, 9, 1321. [Google Scholar] [CrossRef]
  93. Sessa, F.; Maglietta, F.; Bertozzi, G.; Salerno, M.; Di Mizio, G.; Messina, G.; Montana, A.; Ricci, P.; Pomara, C. Human brain injury and mirnas: An experimental study. Int. J. Mol. Sci. 2019, 20, 1546. [Google Scholar] [CrossRef] [Green Version]
Figure 1. Flow diagram with inclusion and exclusion criteria for the selection of sources for the purpose of the review.
Figure 1. Flow diagram with inclusion and exclusion criteria for the selection of sources for the purpose of the review.
Medicina 56 00587 g001
Figure 2. Summary of macroscopic and histologic findings.Autopsies ruled out the causes of extracardiac death in all cases. However, in most cases (20.61%) it was not possible to define the exact cardiac cause that led to death, although SCD was correlated with the use of AASs in all cases.
Figure 2. Summary of macroscopic and histologic findings.Autopsies ruled out the causes of extracardiac death in all cases. However, in most cases (20.61%) it was not possible to define the exact cardiac cause that led to death, although SCD was correlated with the use of AASs in all cases.
Medicina 56 00587 g002
Table 1. Articles included.
Table 1. Articles included.
AuthorYearNumber of CasesStudy Type
Campbell, S.E. et al. [37]19931Case report
Dickerman, R.D. et al. [38]19951Case report
Hausmann, R. et al. [39]19981Case report
Fineschi, V. et al. [40]20012Case series
Fineschi, V. et al. [41]20071 1Case series
Di Paolo, M. et al. [42]20074Letter to the editor
Fanton, L. et al. [43]20096 2Retrospective study
Thiblin, I. et al. [44]20091Case report
Montisci, M. et al. [45]20123 3Case series
Lusetti, M. et al. [46]20156Retrospective study
Lichtenfeld, J. et al. [47]20161Case report
Lusetti, M. et al. [48]20185Retrospective study
Hernandez-Guerra, A.I. et al. [1]20191Case report
1 case excluded because already present in the previous article; 2 only 6 out of 12 cases died of sudden cardiac death (SCD); 3 3 out of 4 cases died of SCD.
Table 2. Anabolic-androgenic steroids (AASs) found on toxicological analysis.
Table 2. Anabolic-androgenic steroids (AASs) found on toxicological analysis.
Toxicological FindingsNumber of Cases% of Total Cases
Nandrolone1030%
Testosterone927%
Stanozolol721%
Boldenon26%
Norandrosterone13%
Mesterolone13%
Methandienone13%
Epitestosterone13%
Nortestosterone13%
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Torrisi, M.; Pennisi, G.; Russo, I.; Amico, F.; Esposito, M.; Liberto, A.; Cocimano, G.; Salerno, M.; Li Rosi, G.; Di Nunno, N.; et al. Sudden Cardiac Death in Anabolic-Androgenic Steroid Users: A Literature Review. Medicina 2020, 56, 587. https://doi.org/10.3390/medicina56110587

AMA Style

Torrisi M, Pennisi G, Russo I, Amico F, Esposito M, Liberto A, Cocimano G, Salerno M, Li Rosi G, Di Nunno N, et al. Sudden Cardiac Death in Anabolic-Androgenic Steroid Users: A Literature Review. Medicina. 2020; 56(11):587. https://doi.org/10.3390/medicina56110587

Chicago/Turabian Style

Torrisi, Marco, Giuliana Pennisi, Ilenia Russo, Francesco Amico, Massimiliano Esposito, Aldo Liberto, Giuseppe Cocimano, Monica Salerno, Giuseppe Li Rosi, Nunzio Di Nunno, and et al. 2020. "Sudden Cardiac Death in Anabolic-Androgenic Steroid Users: A Literature Review" Medicina 56, no. 11: 587. https://doi.org/10.3390/medicina56110587

Article Metrics

Back to TopTop